13 drug(s) with this reaction
60,625 total reports
Off Label Use has been reported as an adverse reaction across 13 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 60,625 adverse event reports mention off label use in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with off label use, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have off label use listed in their FDA adverse event reports, sorted by report count:
In addition to off label use, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
13 drug(s) manufactured by Amgen Inc have off label use listed in their FDA adverse event reports: DENOSUMAB, APREMILAST, PEGFILGRASTIM, FILGRASTIM, ERENUMAB-AOOE, and others.
There are a combined 60,625 reports of off label use across 13 Amgen Inc drug(s) in the FDA adverse event database.